We are live on ! Find out more
NUVB.WS

Nuvation Bio Inc Warrants

Delisted

NUVB.WS was delisted on the 10th of February, 2026.

20 hedge funds and large institutions have $2.81M invested in Nuvation Bio Inc Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.06% less ownership

Funds ownership: 1.87%1.81% (-0.06%)

9% less funds holding

Funds holding: 2220 (-2)

32% less capital invested

Capital invested by funds: $4.11M → $2.81M (-$1.3M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

NUVB.WS Hedge Fund Activity: Q3 2022 in Review

20 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio Inc Warrants (NUVB.WS) for Q3 2022, worth a combined $2.81M — down 32% from $4.11M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NUVB.WS and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.

The largest seller was Walleye Capital, exiting entirely with an estimated $22K sold.

  • 20 institutional investors held Nuvation Bio Inc Warrants (NUVB.WS) as of Q3 2022, down from 22 in Q2 2022.
  • Funds reported $2.81M of Nuvation Bio Inc Warrants stock for Q3 2022, down 32% quarter-over-quarter.
  • 0 funds opened new Nuvation Bio Inc Warrants positions in Q3 2022 and 2 closed out, a net change of -2 holders.
  • The largest Nuvation Bio Inc Warrants seller in Q3 2022 was Walleye Capital, an estimated $22K sold.

Based on aggregated 13F filings for Q3 2022.